The Research and Development Center in Lublin has received an occupancy permit. We completed the building on behalf of Synthaverse SA.
The project is part of the emerging Biotechnology Innovation Center – Onko BCG Plant, where technologies related to vaccinology in tuberculosis (BCG) prevention and immunology in cancer therapy will be improved. The occupancy permit is for the Research and Development Center (CBR) building. The second building, Onko BCG, is under construction. KARMAR S.A. is the general contractor for both projects.
„The construction of this facility was an exceptionally demanding project. It was equipped with the most modern technological line in Europe today. The Research and Development Center and the new Onko BCG production facility are our strategic investments with which we have great hopes for development,” stresses Jakub WINKLER, member of the Synthaverse S.A. board of directors.
KARMAR S.A.’s scope of work included comprehensive preparatory and finishing works for the building, as well as installation works, such as chilled water, technical steam, low-pressure gas, gaseous nitrogen, compressed air. The newly built CBR also includes clean rooms of all classes, the construction of which required an executive regime at both the design and execution stages.
The building in numbers:
Karmar S.A. is also the general contractor for the second building, which is being constructed as part of the ONKO BCG Plant – Biotechnology Innovation Center project for Synthaverse SA.
Karmar S.A. has been implementing facilities and laboratory projects for the pharmaceutical industry since 2009. To date, we can boast 10 already completed investments in Gdansk, Warsaw, Lublin and Krakow, among others. Among them, it is worth mentioning the pharmaceutical laboratories for Polpharma Biologics, the construction of a production line of sterile forms on behalf of Polfa Tarchomin and the buildings of the Onko BCG Plant for Synthaverse in Lublin.
